Cerevance Media Center
A New Era in Parkinson’s:
Solengepras Leads the Shift Beyond Dopamine
Solengepras Leads the Shift Beyond Dopamine
Current News
May 3, 2017
Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia
The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance.
December 2, 2016
Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
- Takeda and Lightstone Ventures Participate in Series A Financing
- Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities
News Archive
No items found.
October 7, 2026
Cerevance to Present Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
- Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2
- Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia and motor experiences of daily living (MDS-UPDRS Part II)
- Improvements in daytime sleepiness (Epworth Sleepiness Scale) and quality of life (PDQ-39, exploratory) point to broad motor and non-motor benefit
- Generally well tolerated, with fewer adverse events than those typically associated with dopaminergic adjunctive therapies, and a discontinuation rate similar to placebo
- Cerevance to meet with FDA to discuss the path to a potential New Drug Application
Date:
Start
October 7, 2026
October 7, 2026
end
Time:
8:00 a.m. KST
Location:
Seoul
Media:
Oral Presentation
February 23, 2026
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
Date:
Monday, March 2, 2026
March 4, 2026
Time:
Scheduled Meetings
Location:
Boston, MA
Media:
One-on-One Meetings
December 1, 2025
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
Date:
Thursday, December 11, 2025
December 11, 2025
Time:
Scheduled Meetings
Location:
Virtual
Media:
One-on-One Meetings
November 24, 2025
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
Date:
Friday, December 5, 2025
December 5, 2025
Time:
Two presentations: 6:15 p.m. – 7:30 p.m. PT and 6 p.m. – 7:30 p.m. PT.
Location:
San Diego, CA
Media:
Poster
Events Archive
No items found.
Cerevance Citations
October 30, 2026

A Binding Site for CVN293 Reveals a Mechanism for Allosteric Control of THIK-1 K2P Channel Gating
February 4, 2026

Discovery of Potent, Selective and Brain-Penetrant Small Molecule CD38 Inhibitors
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021




